Company: HURA
Filing Date: 2025-06-06
Form Type: 8-K
Source: 0001193125-25-137135
Chunk: 0

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On June 2, 2025, TuHURA Biosciences, Inc. (the “ Company”) and investors (the “ Purchasers”) entered into a securities purchase agreement (the “ Securities Purchase Agreement”) pursuant to which the Company agreed to issue to the Purchasers, in a private placement (the “ Offering”), an aggregate of 4.76 million shares (the “ Shares”) of the Company’s common stock, par value $0.001 per share (“ Common Stock”), together with warrants to purchase an equal number of shares of Common Stock at an exercise price of $3.3125 (the “ Warrants”), for an aggregate offering amount of approximately $12.6 million. The combined effective offering price for each Share and accompanying Warrant in the Offering was $2.65.

Pursuant to the Securities Purchase Agreement, each Purchaser will be obligated to purchase such Purchaser’s respective investment in the Offering in four equal tranches, as follows:

  $2.23 million at the initial closing date immediately after the execution of the Securities Purchase Agreement (the “ Initial Closing”);  

  $2.23 million will be purchased on the third business day after the date on which the Company notifies the Purchasers that the Food and Drug Administration (FDA) has notified the Company that t...  

  $2.23 million will be purchased on the third business day after the date on which the Company notifies the Purchasers that the Phase 3 trial for IFx-Hu2.0 (the “ Phase 3 Trial”) has been initia...  

  $2.23 million will be purchased on the third business day after the date on which the Company notifies the Purchasers that all material conditions for the closing of the Company’s proposed merg...  

In addition to the approximately $8.9 million that will be purchased in four equal tranches pursuant to the foregoing milestones, the remaining $3.7 million in the Offering is required to be purchased and funded by December 31, 2025 by certain Purchasers who agreed to invest an aggregate of $4.0 million or more in the Offering and who elected to defer the purchase of a portion of such Purchaser’s Common Stock and Warrants until such time.

The Company received aggregate gross proceeds from the Initial Closing of approximately $2.23 million, before deducting fees to the placement agents and other estimated offering expenses payable by the Company. The Company will receive an additional